

# Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA<sub>1c</sub>, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy

JULIO ROSENSTOCK, MD<sup>1</sup>  
MARISA VICO, MD<sup>2</sup>  
LI WEI, PHD<sup>3</sup>

AFSHIN SALSALI, MD<sup>4</sup>  
JAMES F. LIST, MA, MD, PHD<sup>4</sup>

**OBJECTIVE**—To examine the safety and efficacy of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, added on to pioglitazone in type 2 diabetes inadequately controlled on pioglitazone.

**RESEARCH DESIGN AND METHODS**—Treatment-naïve patients or those receiving metformin, sulfonylurea, or thiazolidinedione entered a 10-week pioglitazone dose-optimization period with only pioglitazone. They were then randomized, along with patients previously receiving pioglitazone  $\geq 30$  mg, to 48 weeks of double-blind dapagliflozin 5 ( $n = 141$ ) or 10 mg ( $n = 140$ ) or placebo ( $n = 139$ ) every day plus open-label pioglitazone. The primary objective compared HbA<sub>1c</sub> change from baseline with dapagliflozin plus pioglitazone versus placebo plus pioglitazone at week 24. Primary analysis was based on ANCOVA model using last observation carried forward; all remaining analyses used repeated-measures analysis.

**RESULTS**—At week 24, the mean reduction from baseline in HbA<sub>1c</sub> was  $-0.42\%$  for placebo versus  $-0.82$  and  $-0.97\%$  for dapagliflozin 5 and 10 mg groups, respectively ( $P = 0.0007$  and  $P < 0.0001$  versus placebo). Patients receiving pioglitazone alone had greater weight gain (3 kg) than those receiving dapagliflozin plus pioglitazone (0.7–1.4 kg) at week 48. Through 48 weeks: hypoglycemia was rare; more events suggestive of genital infection were reported with dapagliflozin (8.6–9.2%) than placebo (2.9%); events suggestive of urinary tract infection showed no clear drug effect (5.0–8.5% for dapagliflozin and 7.9% for placebo); dapagliflozin plus pioglitazone groups had less edema (2.1–4.3%) compared with placebo plus pioglitazone (6.5%); and congestive heart failure and fractures were rare.

**CONCLUSIONS**—In patients with type 2 diabetes inadequately controlled on pioglitazone, the addition of dapagliflozin further reduced HbA<sub>1c</sub> levels and mitigated the pioglitazone-related weight gain without increasing hypoglycemia risk.

*Diabetes Care* 35:1473–1478, 2012

Inhibition of sodium-glucose cotransporter-2 (SGLT2) represents a novel mechanism that reduces hyperglycemia independent of insulin secretion or action (1). In addition, this inhibitory action can induce mild osmotic diuresis and increase urinary

excretion of glucose with modest caloric elimination leading to weight loss (2,3). Dapagliflozin, an SGLT2 inhibitor (4), has been shown to improve glycemic control in patients with type 2 diabetes as monotherapy (5) and in combination with metformin

(6), sulfonylurea (7), or insulin (8), but not yet with a thiazolidinedione.

Some patients with type 2 diabetes use pioglitazone (9), which lowers glucose by altering gene transcription enhancing insulin sensitivity. However, safety concerns of fluid retention, weight gain, congestive heart failure, bone fractures, and, more recently, concerns about bladder cancer has limited its use as second line therapy when metformin is not tolerated or as triple oral therapy (10–14).

The safety hypothesis for a trial combining pioglitazone with dapagliflozin would not be anticipated to worsen the pioglitazone-related side effects and, because dapagliflozin causes glucosuria, which drives diuresis and caloric loss, it may mitigate the concerns of weight gain and fluid retention/edema. This is the first clinical study to examine additive effects of an SGLT2 inhibitor administered in combination with pioglitazone.

## RESEARCH DESIGN AND METHODS

This randomized, double-blind, placebo-controlled, parallel group, 24-week study with a subsequent 24-week extension enrolled male and female patients with type 2 diabetes between 29 July 2008 and 4 July 2009. The study took place at 105 sites in Argentina, Canada, India, Mexico, Peru, Philippines, Taiwan, and United States and was completed on 15 June 2010. Institutional review boards or independent ethics committees approved this protocol, and each patient provided written informed consent.

Patients  $\geq 18$  years old having fasting C-peptide  $\geq 1.0$  ng/mL and BMI  $\leq 45.0$  kg/m<sup>2</sup> entered group A or B. Group A patients had received  $\geq 12$  weeks of pioglitazone 30 or 45 mg/day and had HbA<sub>1c</sub>  $\geq 7.0$  and  $\leq 10.5\%$ . Group B patients were drug naïve for the previous 10 weeks with HbA<sub>1c</sub>  $\geq 8.0$  and  $\leq 11.0\%$  or had received pioglitazone 15 mg/day or any dose of rosiglitazone with HbA<sub>1c</sub>  $\geq 8.0$  and

From the <sup>1</sup>Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas; the <sup>2</sup>Instituto de Investigaciones Clínicas Zarate, Buenos Aires, Argentina; <sup>3</sup>Bristol-Myers Squibb, Hopewell, New Jersey; and <sup>4</sup>Bristol-Myers Squibb, Princeton, New Jersey.

Corresponding author: Julio Rosenstock, juliorosenstock@dallasdiabetes.com.

Received 31 August 2011 and accepted 22 February 2012.

DOI: 10.2337/dc11-1693. Clinical trial reg. no. NCT00683878, clinicaltrials.gov.

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1693/-/DC1>.

A complete list of the principal investigators can be found in the Supplementary Data online.

© 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

≤11.0% or had received ≥8 weeks of metformin ≤1700 mg/day or sulfonylurea less than or equal to half the maximal dose with HbA<sub>1c</sub> ≥7.0 and ≤11.0%. Group B patients could not be on >1 oral antidiabetic medication, and patients on more than half the maximum dose of sulfonylurea or metformin were excluded. Group B patients underwent a 10-week dose-optimization period in which their initial therapy was discontinued, and pioglitazone 30 mg/day was started and increased to 45 mg/day if possible. Group B patients were discontinued if their fasting plasma glucose (FPG) was >270 mg/dL (15.0 mmol/L) after 3 weeks or after 6 weeks with HbA<sub>1c</sub> <7.0 or >11.0%. Exclusion criteria included aspartate or alanine aminotransferases >2.5 times the upper limit of normal, total bilirubin >2.0 mg/dL, serum creatinine ≥2.0 mg/dL, urine albumin/creatinine ratio >1,800 mg/g, calculated creatinine clearance <50 mL/min, and congestive heart failure class III and IV.

Patients with prerandomization HbA<sub>1c</sub> ≥7.0 and ≤10.5% entered the 2-week, single-blind lead-in period and received diet and exercise counseling. Randomized patients received double-blind dapagliflozin 5 or 10 mg or placebo every day (oral administration) with open-label pioglitazone 30 or 45 mg/day, stratified by pre-enrollment diabetes treatment group A and B. To ensure adequate representation from group A, randomization was set to recruit at least one-third of the patients from this group.

The primary objective compared the change at 24 weeks from baseline in HbA<sub>1c</sub> with each dose of dapagliflozin plus pioglitazone versus placebo plus pioglitazone. Secondary objectives included change from baseline in FPG, postprandial glucose (PPG) measured by 120-min post-challenge response to an oral glucose tolerance test, and total body weight.

If FPG was >270 mg/dL (15.0 mmol/L) (week 4–8), >240 mg/dL (13.3 mmol/L) (week 8–12), or >200 mg/dL (11.1 mmol/L) (week 12–24), then patients were eligible to receive open-label rescue medication (metformin or sulfonylurea). Patients completing the first 24 weeks of the study were eligible for an additional 24 weeks. During weeks 24 to 48, if HbA<sub>1c</sub> was >8.0 (week 25–36) or >7.5% (week 36–47), patients were eligible to receive open-label rescue medication. Data obtained after rescue were excluded from the efficacy analysis but included in safety analysis.

Adverse events, laboratory abnormalities, and vital signs were assessed for the

safety and tolerability of treatment. Hypoglycemia definitions are in the Supplementary Appendix and were documented for any event the investigator considered to be a hypoglycemic event, regardless of blood glucose measurement. Signs, symptoms, and events suggestive of urinary tract infection (UTI) and genital infection were solicited at every visit. Preferred term lists included a broad spectrum of signs and symptoms of UTIs and genital infections in addition to specific diagnoses. Seated blood pressure was determined after 5 min of rest followed by the orthostatic blood pressure measurements. Average blood pressure was determined from three replicate measurements taken at least 1 min apart in each position (seated, supine, and standing).

### Statistical analyses

Statistical analyses at week 24 (last observation carried forward) including changes from baseline in HbA<sub>1c</sub>, FPG, PPG, and body weight were performed using ANCOVA with treatment group as an effect and baseline value and strata based on pre-enrollment antidiabetic therapy as covariates in the model. Secondary end points were tested for significance sequentially.

At week 48, analyses of change from baseline in HbA<sub>1c</sub>, FPG, PPG, and body weight were performed using longitudinal repeated-measures analysis over time

including the fixed categorical effects of strata based on pre-enrollment antidiabetic therapy, treatment, week, and treatment-by-week interaction as well as the continuous fixed covariates of baseline measurement and baseline measurement-by-week interaction. No statistical testing was performed for the 48-week long-term period. Rescue was added as an additional effect to the mixed model when the analysis was performed on data regardless of rescue.

**RESULTS**—Of the 972 enrolled patients, 558 met the entrance criteria, and 480 entered the lead-in phase with pioglitazone. Almost equal numbers of patients came from group A (48%, 200 out of 420) and group B (52%, 220 out of 420) (Supplementary Fig. 1). Demographics and baseline characteristics are shown in Table 1. The proportion of patients who were discontinued or rescued for lack of glycemic control was less with dapagliflozin (11–18%) than with placebo (34%).

Treatment with dapagliflozin 5 and 10 mg added on to pioglitazone resulted in statistically significant mean reductions in HbA<sub>1c</sub>, FPG, and PPG when compared with placebo at week 24 (Table 2) and were maintained through week 48 (Table 2). The mean reduction from baseline in HbA<sub>1c</sub> with dapagliflozin plus pioglitazone

**Table 1—Demographics and baseline characteristics**

	Placebo + pioglitazone ≥30 mg	Dapagliflozin 5 mg + pioglitazone ≥30 mg	Dapagliflozin 10 mg + pioglitazone ≥30 mg
n	139	141	140
Age (years)	53.5 ± 11.4	53.2 ± 10.9	53.8 ± 10.4
Men	71 (51.1)	78 (55.3)	59 (42.1)
Women	68 (48.9)	63 (44.7)	81 (57.9)
Race			
White	102 (74.3)	102 (72.3)	101 (72.1)
African American	6 (4.3)	9 (6.4)	7 (5.0)
Asian	24 (17.3)	26 (18.4)	21 (15.0)
Other	7 (5.0)	4 (2.8)	11 (7.9)
HbA <sub>1c</sub> (%)	8.34 ± 1.00	8.40 ± 1.03	8.37 ± 0.96
FPG (mg/dL)	160.7 ± 47.0	168.6 ± 52.1	164.9 ± 46.3
FPG (mmol/L)	8.92 ± 2.61	9.36 ± 2.89	9.15 ± 2.57
120-min PPG (mg/dL)	294 ± 81	285 ± 99	308 ± 93
120-min PPG (mmol/L)	16.3 ± 4.50	15.8 ± 5.49	17.1 ± 5.17
Weight (kg)	86.4 ± 21.3	87.8 ± 20.7	84.8 ± 22.2
BMI			
≥30 kg/m <sup>2</sup>	85 (61.2)	87 (61.7)	72 (51.4)
≥25 kg/m <sup>2</sup>	122 (87.8)	122 (86.5)	130 (92.9)
Duration of diabetes (years)	5.07 ± 5.05	5.64 ± 5.36	5.75 ± 6.44

Data are means ± SD or n (%).

ranged from -0.82 to -0.97% compared with -0.42% with the placebo plus pioglitazone at week 24 (P = 0.0007 and P < 0.0001 for dapagliflozin 5- and 10-mg groups, respectively.) At 48 weeks, the mean reductions in HbA<sub>1c</sub> were maintained, and dapagliflozin groups ranged from -0.95 to -1.21% compared with -0.54% with the placebo plus pioglitazone. These reductions were dose-dependent (Fig. 1A) and similar between groups A and B over time (data not shown). Rapid decreases in FPG were observed at week 1 (Fig. 1B) in the dapagliflozin groups and significant at week 24 (Table 2). At week 48, a greater reduction in mean change from baseline in PPG was observed with dapagliflozin plus pioglitazone (-60.4 to -80.9 mg/dL [-3.35 to -4.49 mmol/L]) than with placebo plus pioglitazone (-25.4 mg/dL [1.41 mmol/L]) (Table 2).

The increase in mean urinary glucose to creatinine ratio from baseline was maintained in the dapagliflozin groups over time (Fig. 1C). The placebo group experienced a mean increase in body weight of 3.0 kg through week 48. Dapagliflozin groups had a slight weight reduction initially, followed by gradual weight gain toward the baseline values at week 24 and gains of 1.4 and 0.7 kg for 5 and 10 mg, respectively, at week 48 (Table 2 and Fig. 1D). These changes for the dapagliflozin groups were significant at week 24 compared with placebo, maintained throughout 48 weeks (Table 2), and appeared to be dose-dependent over time (Fig. 1D).


The placebo group experienced a mean increase in seated blood pressure at weeks 24 and 48, whereas both dapagliflozin groups experienced mean decreases (Table 2). Small mean increases in hematocrit occurred in both dapagliflozin treatment groups (1.36–2.04%), whereas the placebo showed -0.44% change at week 48. Small changes were observed on mean fasting LDL cholesterol (1.1–3.4% for dapagliflozin and 4.5% for placebo), total cholesterol (0.0–2.0% for dapagliflozin and 1.9% for placebo), triglycerides (3.7–4.2% for dapagliflozin and 13.5% for placebo), and HDL cholesterol (4.1–7.2% for dapagliflozin and 1.3% for placebo) at week 48.

No clinically relevant changes in calcium, magnesium, phosphorous, or serum 25 hydroxyvitamin D concentrations were apparent in any treatment group throughout the study (data not shown). There were small increases within the normal limits for parathyroid hormone

Table 2—Change from baseline at weeks 24 and 48 in efficacy parameters, vital signs, and laboratory values

n	Week 24				Week 48			
	Placebo + pioglitazone ≥30 mg	Dapagliflozin 5 mg + pioglitazone ≥30 mg	Dapagliflozin 10 mg + pioglitazone ≥30 mg	140	Placebo + pioglitazone ≥30 mg	Dapagliflozin 5 mg + pioglitazone ≥30 mg	Dapagliflozin 10 mg + pioglitazone ≥30 mg	140
HbA <sub>1c</sub> (%)*†	-0.42 ± 0.08	-0.82 ± 0.08‡	-0.97 ± 0.08§	140	-0.54 ± 0.08	-0.95 ± 0.08	-1.21 ± 0.07	140
FPG (mg/dL)*†	-5.5 ± 2.9	-24.9 ± 2.9§	-29.6 ± 2.9§	141	-13.1 ± 3.6	-22.8 ± 3.2	-33.1 ± 3.0	140
FPG (mmol/L)*†	-0.31 ± 0.16	-1.38 ± 0.16§	-1.64 ± 0.16§	141	-0.73 ± 0.20	-1.27 ± 0.18	-1.84 ± 0.17	140
120 min PPG (mg/dL)*	-14.1 ± 6.4	-65.1 ± 6.3§	-67.5 ± 6.4§	141	-25.4 ± 7.1	-60.4 ± 5.9	-80.9 ± 5.7	140
120 min PPG (mmol/L)*	-0.78 ± 0.36	-3.61 ± 0.35§	-3.75 ± 0.36§	141	-1.41 ± 0.39	-3.35 ± 0.33	-4.49 ± 0.32	140
Weight (kg)*†	1.64 ± 0.28	0.09 ± 0.28§	-0.14 ± 0.28§	141	2.99 ± 0.41	1.35 ± 0.38	0.69 ± 0.36	140
Seated systolic blood pressure (mmHg)	1.3 ± 1.2	-0.8 ± 1.2	-3.4 ± 1.2	141	2.0 ± 1.2	-1.0 ± 1.1	-2.2 ± 1.2	140
Seated diastolic blood pressure (mmHg)	0.7 ± 0.8	-1.0 ± 0.7	-3.1 ± 0.8	141	0.4 ± 0.9	-0.7 ± 0.7	-2.4 ± 0.7	140
Urinary glucose/creatinine ratio¶	1.56 ± 22.1	35.7 ± 32.4	43.7 ± 37.1	141	-1.74 ± 10.6	30.4 ± 28.7	38.4 ± 28.6	140
Serum creatinine (μmol/L)	-0.44 ± 0.68	-1.24 ± 0.72	1.24 ± 0.83	141	0.62 ± 1.10	0.62 ± 1.04	2.12 ± 0.86	140
Serum uric acid (μmol/L)	11.3 ± 3.90	-19.6 ± 5.46	-26.2 ± 4.70	141	—	—	—	140
Blood urea nitrogen (mmol/L)	-0.088 ± 0.12	0.46 ± 0.14	0.46 ± 0.13	141	-0.37 ± 0.14	0.40 ± 0.16	0.35 ± 0.16	140
Sodium (mmol/L)	-0.2 ± 0.2	0.4 ± 0.2	0.7 ± 0.2	141	0.2 ± 0.2	0.7 ± 0.3	1.4 ± 0.2	140
Potassium (mmol/L)	0.02 ± 0.04	-0.05 ± 0.03	0.01 ± 0.04	141	0.05 ± 0.03	-0.05 ± 0.04	-0.02 ± 0.03	140
Parathyroid hormone (pg/mL)	0.4 ± 1.2	4.6 ± 1.2	4.2 ± 1.4	141	2.7 ± 1.5	10.6 ± 6.7	7.3 ± 1.4	140
Serum albumin (g/dL)	-0.02 ± 0.02	0.02 ± 0.02	-0.01 ± 0.02	141	-0.06 ± 0.03	-0.01 ± 0.03	0.01 ± 0.03	140

Data are mean change from baseline ± SE unless otherwise indicated and excludes data after rescue except serum uric acid, which included data after rescue. \*Adjusted mean change from baseline. †Weeks 24 and 48 were based on ANCOVA model using last observation carried forward and repeated-measures analysis, respectively. ‡P = 0.0007 versus placebo. §P < 0.0001 versus placebo. ||Measured by 120-min postchallenge response to an oral glucose tolerance test. ¶Mean change from baseline ± SD.



**Figure 1**—Changes in glycemic parameters for placebo (circles), dapagliflozin 5 mg (squares), and dapagliflozin 10 mg (triangles) all plus pioglitazone  $\geq 30$  mg. A: Mean change from baseline in HbA<sub>1c</sub> after adjustment for baseline value over time. B: Mean change from baseline in FPG after adjustment for baseline value over time. C: Mean urinary glucose to creatinine ratio change from baseline over time. D: Mean change from baseline in total body weight after adjustment for baseline value over time. Includes patients who took at least one dose of double-blind study medication. Error bars represent 95% CIs. Treatment symbols shifted horizontally to prevent error bars from overlapping.

and small mean changes in bone markers (serum procollagen type 1 N-propeptide, COOH-terminal telopeptide of type 1 collagen, N-terminal telopeptide of type 1 collagen, and osteocalcin) compared with placebo, which were unlikely to be clinically significant.

Table 3 describes the adverse events through week 48. The proportion of patients who reported at least one adverse event was similar for dapagliflozin (68.1–70.7%) and placebo (66.9%) through week 48. One death due to septic shock was reported on day 117 in the dapagliflozin 5-mg group within 2 days of presenting with acute cholecystitis. Discontinuations were low and similar between the dapagliflozin and the placebo groups, none due to hypoglycemia. No major episodes of hypoglycemia occurred during the 48-week study.

All of the renal events listed in Table 3 occurred during the first 24-week period, and no additional events occurred during

the second 24-week period. They included serum creatinine increase (four events), creatinine renal clearance decrease (one event), glomerular filtration rate decrease (one event), and abnormal renal function test (one event). The proportion of patients with an event suggestive of UTI was 7.9, 8.5, and 5.0% with placebo, dapagliflozin 5 mg, and 10 mg, respectively, through week 48. Signs, symptoms, and other events suggestive of genital infection were more common in both dapagliflozin treatment groups (8.6–9.2%) than in the placebo group (2.9%) through week 48. Most events suggestive of UTI or genital infection were of mild or moderate intensity; none of these events were serious or led to withdrawal from the study except for one patient (dapagliflozin 5 mg) with recurrent UTIs.

Patients treated with pioglitazone plus dapagliflozin 5 or 10 mg had a lower rate of peripheral edema (4.3 and 2.1%,

respectively) compared with pioglitazone plus placebo (6.5%) (Table 3). Two patients (one female and one male) from the dapagliflozin 5-mg group experienced limb fractures (one foot and one hand, respectively) during the first 24-week period. One patient on placebo had an event of heart failure, and one patient on dapagliflozin 5 mg had urothelial bladder cancer detected on day 144.

**CONCLUSIONS**—In this study, the addition of dapagliflozin to pioglitazone lowered HbA<sub>1c</sub> levels and attenuated the pioglitazone-related weight gain in patients with type 2 diabetes inadequately controlled on pioglitazone alone. Dapagliflozin acts in the kidney by inhibiting the reabsorption of glucose (15,16) and is not only capable of reducing FPG but also reabsorption of higher glucose load postprandially as shown in this study. These beneficial effects of dapagliflozin on hyperglycemia were

Table 3—Adverse and special interest events through week 48

	Placebo + pioglitazone ≥30 mg	Dapagliflozin 5 mg + pioglitazone ≥30 mg	Dapagliflozin 10 mg + pioglitazone ≥30 mg
<i>n</i>	139	141	140
At least one adverse event	93 (66.9)	96 (68.1)	99 (70.7)
At least one serious adverse event	4 (2.9)	6 (4.3)	2 (1.4)
Adverse event leading to discontinuation of study medication	5 (3.6)	5 (3.5)	3 (2.1)
Most common adverse events (>5% in any treatment group)			
Dyslipidemia	9 (6.5)	11 (7.8)	16 (11.4)
Nasopharyngitis	7 (5.0)	7 (5.0)	11 (7.9)
Diarrhea	6 (4.3)	5 (3.5)	9 (6.4)
Back pain	4 (2.9)	5 (3.5)	8 (5.7)
Upper respiratory tract infection	10 (7.2)	10 (7.1)	7 (5.0)
Headache	10 (7.2)	3 (2.1)	4 (2.9)
Pain in extremity	1 (0.7)	10 (7.1)	4 (2.9)
Edema peripheral	9 (6.5)	6 (4.3)	3 (2.1)
Adverse events of special interest			
Suggestive of urinary tract infection	11 (7.9)	12 (8.5)	7 (5.0)
Suggestive of genital infection	4 (2.9)	13 (9.2)	12 (8.6)
Mycotic genital infection	1 (0.7)	8 (5.7)	6 (4.3)
Decreased renal function	1 (0.7)	2 (1.4)	2 (1.4)
Fracture	0	2 (1.4)	0
Total patients with hypoglycemia	1 (0.7)	3 (2.1)	0
Major episode of hypoglycemia*	0	0	0
Congestive heart failure	1 (0.7)	0	0
Bladder cancer†	0	1 (0.7)	0

Data are *n* (%). \*Major episode defined as a symptomatic episode requiring external assistance due to severe impairment in consciousness or behavior with a capillary or plasma glucose value <54 mg/dL (<3.0 mmol/L) and prompt recovery after glucose or glucagon administration. Minor episodes defined as either a symptomatic episode with a capillary or plasma glucose measurement <63 mg/dL (3.5 mmol/L) regardless of need for external assistance or an asymptomatic capillary or plasma glucose measurement <63 mg/dL (3.5 mmol/L), which does not qualify as a major episode. Other episodes defined as episodes reported by the investigator that are suggestive of hypoglycemia but do not meet the above criteria. †Urothelial bladder carcinoma.

maintained for almost 1 year and were consistent with sustained pharmacodynamic activity on glycosuria.

The glucosuria induced by SGLT-2 inhibition might be suspected to lead to hypoglycemia, UTIs, and genital infections. However, hypoglycemia events were rare in this study. No clear relationship to dapagliflozin was observed for events suggestive of UTIs, although one patient withdrew from the trial due to recurring UTIs. Consistent with previous reports (5,6,8), events suggestive of genital infections were higher in patients on dapagliflozin than on placebo. None of these genital infections were

serious, and all responded to antimicrobial treatment.

Urinary excretion of glucose also leads to caloric loss and the addition of dapagliflozin to pioglitazone can potentially mitigate weight gain due to pioglitazone. The differences between placebo and dapagliflozin-treated groups in weight were mainly driven by continuous weight gain in the placebo group, reflecting probably that pioglitazone was initiated or optimized during the prerandomization period, whereas no meaningful changes from baseline occurred in dapagliflozin groups. Dapagliflozin, acting as a mild diuretic, may also mitigate the fluid retaining effects of

pioglitazone as evidenced by fewer reports of edema.

Some studies suggest that pioglitazone may modestly lower blood pressure (17), a beneficial effect for patients with diabetes. When dapagliflozin was used as monotherapy (5) or in combination therapy (6,8), there was also some suggestive mild lowering of blood pressure. In this study, addition of dapagliflozin to pioglitazone was associated with a modest further decrease in blood pressure beyond the effect of pioglitazone alone in the absence of any ill effects such as hypotensive events or measured orthostatic hypotension. Thus, along with effects on weight, dapagliflozin may add to the blood pressure benefit of pioglitazone.

Congestive heart failure, bladder cancer, or bone fractures, known side effects of long-term use of pioglitazone, were rare events; too rare at this stage to infer any effect on the risk of these events with the addition of dapagliflozin (13,14,18). Two fractures did occur in the dapagliflozin 5-mg group, but all patients received pioglitazone, and thiazolidinediones are known to increase the risk of fractures (19).

Dapagliflozin added on to pioglitazone resulted in sustained glycemic benefits in both fasting and postprandial plasma glucose concentrations. As a possible mild diuretic and consistent glucoretic, dapagliflozin mitigated the weight gain and fluid retention due to pioglitazone. Even though more genital infections occurred with dapagliflozin than placebo, dapagliflozin added on to pioglitazone was effective and well-tolerated. The direct removal of glucose by dapagliflozin complements the insulin-sensitizing action of pioglitazone, providing a potential combination that balances well the benefits and risks of therapy for some patients with type 2 diabetes.

**Acknowledgments**—This Bristol-Myers Squibb and AstraZeneca-supported study is also known as Study MB102030. J.R. has served on scientific advisory boards and received honorarium or consulting fees from Pfizer, Roche, sanofi-aventis, Novo Nordisk, Eli Lilly, MannKind, GlaxoSmithKline, Takeda, Daiichi Sankyo, Johnson & Johnson, Novartis, Boehringer Ingelheim, Lexicon, and Amylin. J.R. has received grants/research support from Merck, Pfizer, sanofi-aventis, Novo Nordisk, Roche, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Takeda, Novartis, AstraZeneca, Amylin, Johnson & Johnson, Daiichi Sankyo, MannKind, and Boehringer Ingelheim. L.W., A.S., and J.F.L. are employees and shareholders of Bristol-Myers Squibb. No other potential

conflicts of interest relevant to this article were reported.

J.R., M.V., L.W., and A.S. analyzed and interpreted data, contributed to the discussion, and reviewed/edited the manuscript. J.F.L. analyzed and interpreted data, contributed to the discussion, reviewed/edited the manuscript, and wrote the manuscript. J.F.L. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Parts of this study were presented at the 71st Scientific Sessions of the American Diabetes Association, San Diego, California, 24–28 June 2011, and at the 47th Annual Meeting of the European Association for the Study of Diabetes, Lisbon, Portugal, 12–16 September 2011.

The authors thank Carolyn Carroll, PhD, Bristol-Myers Squibb, for professional medical writing and editorial assistance. The authors also thank the patients for participation and commitment during the study.

## References

1. Idris I, Donnelly R. Sodium-glucose cotransporter-2 inhibitors: an emerging new class of oral antidiabetic drug. *Diabetes Obes Metab* 2009;11:79–88
2. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. *Clin Pharmacol Ther* 2009;85:513–519
3. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. *Diabetes Care* 2009;32:650–657
4. Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. *J Med Chem* 2008;51:1145–1149
5. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. *Diabetes Care* 2010;33:2217–2224
6. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomized, double-blind, placebo-controlled trial. *Lancet* 2010;375:2223–2233
7. Strojek K, Yoon KH, Hrubá V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. *Diabetes Obes Metab* 2011;13:928–938
8. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. *Diabetes Care* 2009;32:1656–1662
9. McGuire DK, Inzucchi SE. New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications. *Circulation* 2008;117:440–449
10. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. *Diabetes Care* 2007;30:2148–2153
11. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. *Arch Intern Med* 2008;168:820–825
12. Nathan DM, Buse JB, Davidson MB, et al.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2009;32:193–203
13. Actos prescribing information [Internet]. 2011. Available from <http://www.actos.com>. Accessed 17 November 2011
14. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. *Diabetes Care* 2011;34:916–922
15. Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na<sup>+</sup>/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. *J Clin Invest* 1994;93:397–404
16. Washburn WN. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. *J Med Chem* 2009;52:1785–1794
17. Sarafidis PA, Nilsson PM. The effects of thiazolidinediones on blood pressure levels - a systematic review. *Blood Press* 2006;15:135–150
18. Hillaire-Buys D, Faillie J-L, Montastruc J-L. Pioglitazone and bladder cancer. *Lancet* 2011;378:1543–1544; author reply 1544–1545
19. Riche DM, King ST. Bone loss and fracture risk associated with thiazolidinedione therapy. *Pharmacotherapy* 2010;30:716–727